NCT00400985 - Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure | Biotech Hunter

Enrollment

501

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Heart Failure, Congestive

Interventions

DEVICE

Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.

SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.

Trial Locations (2)

UZA, Antwerp

Royal Brompton, London